Barclays’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Barclays’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,100	Closed	-$270K	–	5270
2023 Q1	$270K	Buy	+11,100	New	+$243K	﹤0.01%	3635
2018 Q1	–	Sell	-1,800	Closed	-$6K	–	7429
2017 Q4	$6K	Sell	1,800 -1,000	-36%	-$2.81K	﹤0.01%	6649
2017 Q3	$8K	Hold	2,800	–	–	﹤0.01%	6251
2017 Q2	$7K	Buy	2,800 +2,300	+460%	+$6.26K	﹤0.01%	6168
2017 Q1	$2K	Sell	500 -665,900	-100%	-$2.81M	﹤0.01%	6509
2016 Q4	$3.22M	Buy	666,400 +544,300	+446%	+$16.2M	﹤0.01%	1727
2016 Q3	$5.63M	Buy	+122,100	New	+$6.89M	0.01%	1206

Barclays's ISEE Position: Q3 2023 in Review

Barclays sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 235,648 shares — an estimated $9.27M sold.

Barclays first reported a position in ISEE in Q4 2013 and held it in 33 quarters. The position peaked at $17.5M in Q1 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

Barclays reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Barclays sold 235,648 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $9.27M.
Barclays first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 33 quarters.
Barclays's IVERIC bio, Inc. Common Stock position peaked at $17.5M in Q1 2023.
0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.